August 03, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
The FDA has expanded approval for a radioligand therapy that nearly doubles the number of men with advanced prostate cancer eligible to receive the treatment, according to a Novartis press release.Men with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer can now use lutetium Lu-177 vipivotide tetraxetan (Pluvicto, Novartis) in combination with an
407 words~2 min read
